Rutgers, The State University of New Jersey clinical trials
Rutgers, The State University of New Jersey is the lead sponsor of 10 current clinical trials in our Israel register. 8 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, 5Fluorouracil and Abraxane. The most-studied condition is HER2-positive Early-stage Breast Cancer.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Rutgers, The State University of New Jersey
10 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
NCT07402473 · HER2-positive Early-stage Breast Cancer
|
Phase 2 | Recruiting | 2026-03 | Israel |
|
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
NCT05332002 · ClinicalTrials.gov ↗ · Gastro-Intestinal Cancer
|
Phase 2 | Recruiting | 2022-07 | Israel |
|
COMMETS- Combination MCI Metabolic Syndrome
NCT06072963 · ClinicalTrials.gov ↗ · Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
Drug: Semaglutide |
Phase 2 | Recruiting | 2024-01 | Israel |
|
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT05559164 · ClinicalTrials.gov ↗ · Cardiac Toxicity, Early-stage Breast Cancer
Drug: Lipitor |
Phase 2 | Recruiting | 2022-09 | Israel |
|
Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4
NCT06797219 · ClinicalTrials.gov ↗ · Intraventricular Hemorrhage of Prematurity, Hydrocephalus
|
Not applicable | Recruiting | 2025-02 | Israel |
|
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07158164 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Drugs: Fluorouracil, Xeloda |
Phase 4 | Recruiting | 2025-08 | Israel |
|
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer
|
Phase 2 | Recruiting | 2022-04 | Israel |
|
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT06518837 · ClinicalTrials.gov ↗ · Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Drug: Tirzepatide |
Phase 2 | Recruiting | 2024-10 | Israel |
|
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
NCT05333874 · ClinicalTrials.gov ↗ · Breast Cancer, Early-Onset
|
Early Phase 1 | Active, closed | 2022-04 | Israel |
|
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT04871516 · ClinicalTrials.gov ↗ · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
|
Not applicable | Active, closed | 2021-05 | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Rutgers, The State University of New Jersey trials
17 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Rutgers, The State University of New Jersey trials
22 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Israel | 10 | 8 |
A trial with sites in more than one country appears in each of those registers.
Questions about Rutgers, The State University of New Jersey trials
How many clinical trials does Rutgers, The State University of New Jersey sponsor?
Rutgers, The State University of New Jersey is the lead sponsor of 10 current trials on ClinicalTrials.gov in our Israel register, as of the registry sync on 15 November 2026. Completed and withdrawn studies are not counted.
Are Rutgers, The State University of New Jersey trials recruiting?
Yes. 8 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Rutgers, The State University of New Jersey testing?
Its current trials name 17 drugs and biologicals as interventions. The most frequent are Carboplatin (2), 5Fluorouracil (1), Abraxane (1), Adrucil (1) and Docetaxel (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 15 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.